Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 5/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119886 | 0.83 | RAB9A (0.47) | EPHX2LMNAALDH1A1GRM5IGF1R | |
| SCHEMBL13875377 | 0.83 | RET (0.37) | EPHX2LMNAALDH1A1THRBRAB9A | |
| SCHEMBL25796811 | 0.83 | EPHX2 (0.35) | EPHX2LMNAALDH1A1IGF1RTHRB | |
| Hydrochloric Acid SCHEMBL4168440 | 0.82 | RET (0.36) | EPHX2THRBRAB9ARETSMN1; SMN2 | |
| SCHEMBL442507 | 0.81 | NOTUM (0.43) | EPHX2LMNAALDH1A1GRM5IGF1R | |
| SCHEMBL1106840 | 0.81 | ALDH1A1 (0.43) | EPHX2LMNAALDH1A1GRM5RAB9A | |
| SCHEMBL2306096 | 0.81 | LMNA (0.45) | EPHX2LMNAALDH1A1GRM5IGF1R | |
| SCHEMBL9386575 | 0.81 | EPHX2 (0.41) | EPHX2LMNAALDH1A1GRM5IGF1R | |
| SCHEMBL745934 | 0.81 | ALDH1A1 (0.49) | EPHX2LMNAALDH1A1GRM5IGF1R | |
| Hydrochloric Acid SCHEMBL19555684 | 0.79 | NOTUM (0.42) | EPHX2LMNAALDH1A1GRM5IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11560381-B1 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11384074-B2 | Pesticidally active pyrrole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2022-07-12 | — | — | US | disclosed |
| US-11377422-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-07 | — | — | US | disclosed |
| US-8507723-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120322878-A1 | Polycationic Compounds And Uses Thereof | POLYMEDIX, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120172291-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2012-07-05 | — | — | US | disclosed |
| US-20120101031-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-8129566-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
| US-20110124664-A1 | Polycationic Compounds And Uses Thereof | POLYMEDIX, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20090239811-A1 | POLYCATIONIC COMPOUNDS AND USES THEREOF | POLYMEDIX, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20070189865-A1 | Amino cyclopropane carboxamide derivatives as bradykinin antagonists | MERCK & CO., INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070189865-A1 | Amino cyclopropane carboxamide derivatives as bradykinin antagonists | MERCK & CO., INC. | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101031-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, PRSS1, SPINT2 | EPHX2 756/4885LMNA 2577/4885ALDH1A1 1994/4885 |
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | EPHX2 4457/4885LMNA 2775/4885ALDH1A1 2900/4885 |
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | EPHX2 784/4885LMNA 1722/4885ALDH1A1 3157/4885 |
| US-20120172291-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, PRSS1, SPINT2 | EPHX2 762/4885LMNA 2363/4885ALDH1A1 1770/4885 |
| US-11384074-B2 | Pesticidally active pyrrole derivatives | ACHE, DDT, CAT | EPHX2 1135/4885LMNA 2848/4885ALDH1A1 475/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | EPHX2 1990/4885LMNA 334/4885ALDH1A1 4542/4885 |
| US-11377422-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | EPHX2 746/4885LMNA 2685/4885ALDH1A1 2736/4885 |
| US-20120322878-A1 | Polycationic Compounds And Uses Thereof | VEGFA, VHL, PGF | EPHX2 1592/4885LMNA 3716/4885ALDH1A1 3071/4885 |
| US-20110124664-A1 | Polycationic Compounds And Uses Thereof | VEGFA, VHL, PGF | EPHX2 1592/4885LMNA 3716/4885ALDH1A1 3071/4885 |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | EPHX2 1579/4885LMNA 2339/4885ALDH1A1 4654/4885 |
| US-20090239811-A1 | POLYCATIONIC COMPOUNDS AND USES THEREOF | VEGFA, VHL, PGF | EPHX2 1592/4885LMNA 3716/4885ALDH1A1 3071/4885 |
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | EPHX2 2455/4885LMNA 1347/4885ALDH1A1 172/4885 |
| US-11560381-B1 | Compounds and uses thereof | VHL, TFEB, BECN1 | EPHX2 2372/4885LMNA 172/4885ALDH1A1 1358/4885 |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | TRPV1, TRPV5, TRPA1 | EPHX2 1379/4885LMNA 3757/4885ALDH1A1 3411/4885 |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | TRPV1, TRPA1, TRPV2 | EPHX2 370/4885LMNA 2730/4885ALDH1A1 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.